Session 1: Novel Insights Into the Pathogenesis of CLL

Co-Chair(s)

• 

  Catherine Wu, MD

  Professor of Medicine
  Dana-Farber Cancer Institute, Harvard Medical School
  Boston, Massachusetts, United States
• 

  Stephan Stilgenbauer, MD

  Professor of Medicine, Medical Director
  Division of CLL, Internal Medicine III, Ulm University
  Ulm, Baden-Wurttemberg, Germany

Presentations:

• 08:40 - 08:55 CEST

  Insights into Pathogenesis from Germline Predisposition / Familial CLL Studies, Including MBL
  

  Speaker: Susan Slager, PhD – Department of Quantitative Health Sciences, Division of Hematology, Mayo Clinic
• 08:55 - 09:10 CEST

  Targeting Repressive LEF1/Beta-Catenin Complexes in CLL
  

  Speaker: Markus Müschen, MD-PhD – Yale University
• 09:10 - 09:25 CEST

  Lymphoid CHP
  

  Speaker: Frederik Damm, MD – Dept of Hematology, Oncology, & Cancer Immunology, Charité - Universitätsmedizin Berlin
• 09:25 - 09:40 CEST

  Panel Discussion with Interactivity and Audience Q&A
• 09:40 - 09:50 CEST

  Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia
  

  Primary Author / Presenter: Francesco Angotzi, MD – Hematology Unit, University of Padova
• 09:50 - 10:00 CEST

  ROR1-Signaling Enhances Survival and Drug-Resistance of del(17p)/TP53-Mutated CLL by Mitigating Oxidative Stress Via Activation of NRF2
  

  Primary Author / Presenter: Emanuela M. Ghia, PhD – Center for Novel Therapeutics; University of California, San Diego
• 10:00 - 10:10 CEST

  Clinical and biological impact of MYC Overexpression in Chronic Lymphocytic Leukemia with and without TP53 Disruption
  

  Primary Author / Presenter: Alba Garrote de Barros, MSc – Department of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041
• 10:10 - 10:15 CEST

  IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses
  

  Primary Author / Presenter: Uday Aditya Sarkar, PhD – Dana-Farber Cancer Institute, Harvard Medical School